km.idaeo.ai · IDAEO 知識庫

🏛 本文屬於主題館「reports」 →

植牙全指南（領域總覽）：從評估、骨處理、手術到長期維護｜證據鏈

km 編輯部2026-08-13閱讀約 56 分鐘
#證據鏈#牙醫領域#植牙#假牙

本頁是〈植牙全指南（領域總覽）：從評估、骨處理、手術到長期維護〉的事實單元帳：每一條主張對應的來源、證據等級、地域與期間、原文引句與限制，逐條攤開。

植牙全指南（領域總覽）：從評估、骨處理、手術到長期維護｜證據鏈

十二、F-Units（事實單元帳）

展開 29 條事實單元（來源#／confidence／basis／geo／period／caveat／逐字 span）

F1｜S3｜confidence: high｜basis: peer_reviewed｜geo: universal｜period: 收錄追蹤 ≥20 年之前瞻研究，2026 發表 追蹤 ≥20 年的前瞻研究統合分析：對象為圓柱或錐形螺紋設計的鈦質骨內牙科植體；20 年存活率 93.0%（95% CI 91.6–94.1%），合併平均邊緣骨喪失 1.11 mm（95% CI 0.55–1.68 mm）；GRADE 確定性中等。 span：「assess the 20-year survival rate and marginal bone loss (MBL) of titanium endosseous dental implants with cylindrical or conical screw-shaped designs」／「The 20-year implant survival rate was 93.0% (95% confidence interval 91.6-94.1%)」／「The pooled mean MBL was 1.11 mm (95% confidence interval 0.55-1.68 mm)」／「The certainty of the evidence (GRADE framework) was rated as moderate for both implant survival and MBL; however, this rating was limited by substantial heterogeneity」 caveat：群體層級估計，異質性高，不可推估個人結果；納入研究僅 10 篇。

F2｜S3｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 同 F1 115 例植體失敗中僅 44 例明確報告失敗原因，且生物性與機械性成因的分布幾乎相等。 span：「The specific cause of failure was explicitly reported for 44 of the 115 implants and was almost equally distributed between biological and mechanical causes.」／「These reported 1857 implants (baseline) of which 1028 were followed up for ≥20 years, during which 115 implant failures were recorded.」 caveat：原因分布的分母只有明確報告原因的 44 例，不得寫成整批 115 例失敗或整個 20 年追蹤的成因分布；引用本條時須同時交代這個分母限制。

F3｜S4｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 資料庫檢索至 2024-06 傘狀回顧將「吸菸與植體失敗」的關聯評為 highly suggestive 等級。 span：「25 articles describing 35 associations were included in the study.」／「Highly suggestive evidence was established for the association between smoking and implant failure.」 caveat：觀察性研究關聯，非因果證明。

F4｜S4｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 同 F3 RCT 統合分析中屬高確定性（GRADE）的三組關聯，方向皆為前者與較高的植體失敗風險相關：turned 相較 anodized 表面、submerged 相較 nonsubmerged 癒合、長植體併骨增生相較短植體；觀察性研究中列為 suggestive 的包含牙周條件受損者、骨質分類、負重方案、植體長度等。 span：「turned versus anodized implants, submerged versus nonsubmerged implant healing, and bone augmentation with long implants versus short implants were associated with a higher risk of implant failure (high certainty evidence)」／「Suggestive evidence emerged for associations including periodontally compromised versus periodontally healthy patients」 caveat：關聯方向依比較組定義，不可單獨抽出某一項作絕對判斷。方向不得刪：原文明寫這三組「were associated with a higher risk of implant failure」，只寫「有高確定性證據的關聯」而不寫方向，會讓讀者無從得知哪一側風險較高（其中「長植體併行骨增生 vs 短植體」的方向對「多做骨增生」不利，尤不得省略）。本文未引用該回顧結論段對 anodized 植體的使用建議——器材選擇屬臨床判斷，且本文合規原則為不為任何材料或器材背書。

F5｜S4｜confidence: high｜basis: peer_reviewed｜geo: universal｜period: 同 F3 世代與病例對照研究之統合分析中，沒有任何一組關聯被評為 convincing 等級。 span：「None were graded as convincing.」 caveat：僅適用於該回顧納入的 26 組觀察性統合分析。

F6｜S2｜confidence: high｜basis: clinical_guideline｜geo: universal｜period: 2017 World Workshop（2018 發表） 植體周圍炎＝發生於植體周圍組織、與菌斑相關的病理狀況，特徵為黏膜發炎並伴隨支持骨的進行性喪失；臨床上見發炎徵象、探診出血與／或流膿、探診深度增加與／或黏膜緣退縮，並有影像上骨喪失。 span：「Peri-implantitis is a plaque-associated pathological condition occurring in tissues around dental implants, characterized by inflammation in the peri-implant mucosa and subsequent progressive loss of supporting bone.」／「Peri-implantitis sites exhibit clinical signs of inflammation, bleeding on probing, and/or suppuration, increased probing depths and/or recession of the mucosal margin in addition to radiographic bone loss.」 caveat：為病例定義，非個別診斷；診斷須由臨床醫師執行。

F7｜S2｜confidence: high｜basis: clinical_guideline｜geo: universal｜period: 同 F6 植體周圍黏膜炎主要臨床特徵為輕探即出血，可能併有紅斑、腫脹或流膿；動物與人體實驗研究有強證據指出菌斑為其病因。 span：「The main clinical characteristic of peri-implant mucositis is bleeding on gentle probing. Erythema, swelling, and/or suppuration may also be present.」／「There is strong evidence from animal and human experimental studies that plaque is the etiological factor for peri-implant mucositis.」 caveat：同 F6。

F8｜S2｜confidence: high｜basis: clinical_guideline｜geo: universal｜period: 同 F6 植體周圍健康以無紅斑、無探診出血、無腫脹、無流膿為特徵；無法定義與健康相容的探診深度區間；植體周圍健康可存在於骨支持已減少的植體周圍。 span：「Peri-implant health is characterized by the absence of erythema, bleeding on probing, swelling, and suppuration. It is not possible to define a range of probing depths compatible with health; Peri-implant health can exist around implants with reduced bone support.」 caveat：同 F6。

F9｜S2｜confidence: high｜basis: clinical_guideline｜geo: universal｜period: 同 F6 共識報告建議：臨床醫師應在植體支持的假牙完成後取得基線影像與探診測量。 span：「It is recommended that the clinician obtain baseline radiographic and probing measurements following the completion of the implant-supported prosthesis.」 caveat：為臨床作業建議，非病人自行操作事項。

F10｜S2｜confidence: medium｜basis: clinical_guideline｜geo: universal｜period: 同 F6 角化黏膜對植體周圍組織長期健康的影響證據不一致；但角化黏膜在病人舒適度與清潔難易度上可能有優勢。 span：「The evidence is equivocal regarding the effect of keratinized mucosa on the long-term health of the peri-implant tissue. It appears, however, that keratinized mucosa may have advantages regarding patient comfort and ease of plaque removal.」 caveat：報告自述證據不一致，不可寫成定論。

F11｜S16｜confidence: high｜basis: peer_reviewed｜geo: universal｜period: 2021 發表，納入 28 篇（20 篇可量化） 拔牙後未輔助處置之自然癒合，依「測量方法×牙位」分層合併：臨床測量下非臼齒區水平骨脊縮減平均 2.73 mm（95% CI 2.36–3.11）、中頰側垂直向 1.71 mm（95% CI 1.30–2.12）；影像測量下非臼齒區水平縮減平均 2.54 mm（95% CI 1.97–3.11）、臼齒區水平縮減平均 3.61 mm（95% CI 3.24–3.98）。 span：「Pooled estimates revealed that mean horizontal, vertical mid-facial and mid-lingual ridge reduction assessed clinically in non-molar sites was 2.73 mm (95% CI: 2.36-3.11), 1.71 mm (95% CI: 1.30-2.12) and 1.44 mm (95% CI: 0.78-2.10), respectively.」／「Mean horizontal, vertical mid-facial and mid-lingual ridge reduction assessed radiographically in non-molar sites was 2.54 mm (95% CI: 1.97-3.11), 1.65 mm (95% CI: 0.42-2.88) and 0.87 mm (95% CI: 0.36-1.38), respectively.」／「Mean horizontal, vertical mid-facial and mid-lingual ridge reduction assessed radiographically in molar sites was 3.61 mm (95% CI: 3.24-3.98), 1.46 mm (95% CI: 0.73-2.20) and 1.20 mm (95% CI: 0.56-1.83), respectively.」 caveat：臨床測量與影像測量為不同方法，數字不可互相替換。跨牙位比較只准在同一測量方法內進行（影像法：非臼齒 2.54 vs 臼齒 3.61）；以臨床法的 2.73 對上影像法的 3.61 屬跨方法拼接，不成立。

F12｜S16｜confidence: high｜basis: peer_reviewed｜geo: universal｜period: 同 F11 拔牙窩未輔助癒合所發生的齒槽骨吸收量隨牙位類型而異。 span：「A variable amount of alveolar bone resorption occurs after unassisted socket healing depending on tooth type.」 caveat：僅描述變異存在，未給個別預測值。

F13｜S6｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 2026 發表，納入 53 篇 骨移植材料分四類：自體骨、同種異體骨、異種骨、人工合成材；對何者較優仍無共識，且因高品質證據不足無法下定論。 span：「Fifty-three studies were included.」／「These procedures utilize bone grafting materials of which there are four types, namely, autogenous, allograft, xenograft, and alloplastic grafts. However, there is still no consensus on which material is superior.」／「due to the lack of high-quality evidence in this review, definitive conclusions on which material is superior was not possible」 caveat：各研究方法差異大，無法直接比較結果。

F14｜S6｜confidence: high｜basis: peer_reviewed｜geo: universal｜period: 同 F13 缺牙後的自然生理性骨吸收常導致可用骨量不足以把植體放在贋復需要的位置；因而發展出引導骨再生（GBR）、上顎竇增高（SA）與齒槽脊保存（ARP）等骨再生術式。 span：「The natural physiological bone resorption following tooth loss often results in reduced bone volume to place dental implants in a restoratively driven position. Bone regeneration procedures such as guided bone regeneration (GBR), sinus augmentation (SA), and alveolar ridge preservation (ARP) have therefore been developed to promote new bone formation.」 caveat：術式適用與否為個案判斷。

F15｜S5｜confidence: high｜basis: peer_reviewed｜geo: universal｜period: 2026 發表，納入 100 篇（PROSPERO CRD420251052858） 上顎骨增生術式併發症合併發生率：上顎竇增高 7.98%（95% CI 2.78–15.55）、引導骨再生 26.44%（95% CI 13.06–42.52）、onlay 骨移植 19.61%（95% CI 13.94–25.99）、混合術式 20.10%（95% CI 13.92–27.09）；較常見類型為膜或移植材暴露、傷口裂開與感染。 span：「Of the 2,266 articles reviewed, 100 were selected.」／「Pooled complication rates were: 7.98% (95% CI: 2.78 - 15.55) for sinus lift, 26.44% (95% CI: 13.06 - 42.52) for guided bone regeneration, 19.61% (95% CI: 13.94 - 25.99) for onlay grafting, and 20.10% (95% CI: 13.92 - 27.09) for mixed techniques. The most frequent complications were membrane or graft exposure, wound dehiscence, and infection.」／「The analysis focused on postoperative complications in maxillary bone regeneration techniques.」 caveat：部位限定＝上顎（原文兩處明寫 maxillary），不得外推至下顎骨增生；術式限定＝上顎竇增高／引導骨再生／onlay 骨移植／混合術式四種，未涵蓋齒槽脊保存（ARP），本條不得與含 ARP 的術式清單並句使用。信賴區間寬，異質性大。

F16｜S7｜confidence: high｜basis: peer_reviewed｜geo: universal｜period: 2025-12 發表，11 篇 RCT（IIP 353 人／ARP 348 人） 作者結論：即刻植牙（IIP）可達到與齒槽脊保存（ARP）相當的美觀結果與植體成功情形，但可能有較高的術後併發症發生率與較大的邊緣骨變化。結果段對應數據：美觀分數（PES）MD −0.05（95% CI −0.52 至 0.43）與植體失敗 OR 2.09（95% CI 0.98 至 4.44）兩項未觀察到統計顯著差異；術後併發症一項在 IIP 組較高（p < 0.05）。 span：「Eleven RCTs were included, involving 353 patients in the IIP group and 348 patients in the ARP group.」／「no statistical differences were observed regarding PES (MD = -0.05, 95% CI = -0.52 to 0.43) or implant failure (OR = 2.09, 95% CI = 0.98 to 4.44)」／「both groups achieved similar outcomes in terms of horizontal width change, facial gingival margin change, and patient-reported satisfaction (P > .05), except for a higher incidence of postoperative complications observed in the IIP group (p < 0.05)」／「the IIP protocol can achieve comparable esthetic outcomes and implant success as the ARP protocol; however, there may be a higher incidence of postoperative complications and MBL alterations.」 caveat：作者自述受研究侷限所限，需更長期 RCT 驗證。「相當」的統計意涵限定：結論句的 comparable esthetic outcomes and implant success，對應的是 PES 與植體失敗兩項「未達統計顯著差異」；其中植體失敗的點估計 OR 2.09 偏向即刻植牙較高、95% CI 上限接近 4.5，且僅納入 11 篇試驗（353 人／348 人），檢定力有限——不得把「未達統計顯著」改寫成「兩者失敗風險相當／一樣安全」（absence of evidence ≠ evidence of absence）。對沖詞限定：術後併發症在 CONCLUSION 段寫為「may be」，在 RESULTS 段則為 p < 0.05 的組間差異；正文若寫成斷言，須引 RESULTS 段之 span 並標明為該回顧之結果，不得單憑 CONCLUSION 句去對沖詞。

F17｜S8｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 2026-06 發表，7 篇 RCT、n=589 術前預防性使用口服類固醇或非類固醇抗發炎藥物的系統性回顧，主要結果指標為術後疼痛、水腫、牙關緊閉、不適與救援用藥；因給藥方案與結果指標異質性高，無法就哪一種術前用藥在效果與安全性上較佳得出定論。 span：「The primary outcomes were postoperative pain, edema, trismus, discomfort, and use of rescue medication.」／「Seven RCTs (n = 589 patients)」／「Owing to the heterogeneity in protocols, drug regimens, and outcome measures, definitive conclusions regarding the most effective and safest preemptive agents could not be drawn.」 caveat：本文刻意不引用該回顧中的藥名與劑量（處方行為，且對大眾衛教不宜列出用藥指示）。

F18｜S9｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 2026-01 發表，10 篇隨機安慰劑對照／對照組試驗、合併約 1,950 名參與者 涵蓋各類侵入性牙科處置（含植體植入與拔牙）的隨機效應統合分析：介入定義為全身性抗生素與／或局部抗菌劑預防，合併終點為早期處置相關感染結果與／或菌血症相關終點；預防性抗菌用藥在主要合併終點未顯示統計上顯著的整體降低（MD −0.12，95% CI −0.31 至 0.07；I² 約 99%）；植牙試驗本身事件率低，未一致顯示常規預防用藥具臨床上有意義的優越性。 span：「Prophylactic antimicrobials are frequently administered before invasive dental procedures (including implant placement and extractions)」／「Included studies evaluated perioperative prophylaxis (systemic antibiotics and/or local antiseptic prophylaxis) versus placebo or no prophylaxis in invasive dental procedures.」／「Outcomes were harmonized across studies as early procedure-related infectious outcomes and/or bacteremia-related endpoints」／「Across all invasive dental procedures (~1,950 participants pooled), prophylaxis did not demonstrate a statistically significant overall reduction in the primary pooled endpoint (MD -0.12, 95%CI -0.31 to 0.07; random-effects; I² ≈ 99%)」／「Individual trials showed marked reductions in post-extraction bacteremia surrogates with chlorhexidine mouthwash prophylaxis」／「Implant trials reported low event rates and did not consistently demonstrate clinically meaningful superiority of routine prophylaxis.」／「Funnel plot inspection suggested possible small-study effects influenced by outliers, but interpretation was constrained by extreme between-study heterogeneity.」 metadata 實測（2026-08-06 efetch，HTTP:200）：PubMed 對本篇登錄的 PublicationType 為 `['Journal Article', 'Review']`——未登錄 Systematic Review 或 Meta-Analysis（對照：S10／PMID 32591710 登錄為 `['Journal Article', 'Meta-Analysis', 'Systematic Review']`；S5／PMID 41077306 登錄為 `['Journal Article', 'Systematic Review', 'Meta-Analysis']`）。 caveat：I² 約 99% 屬極高異質性，作者自述解讀受此限制，且 funnel plot 顯示可能存在小研究效應。效應量尺度限定：本條主要合併終點以均差（MD −0.12）合併，與 S10 以風險比（RR 0.47）合併植體失敗屬不同尺度，兩數字不可互換算、不可直接比大小。文獻型別限定：與 S10 並列時須揭露上述 PublicationType 差異，不得逕稱兩者為同層級的「兩派」。引用本條時三項限定不得省略：(a) 介入含局部抗菌劑（個別試驗包含 chlorhexidine 漱口水），不可簡稱為「口服抗生素無效」；(b) 終點含菌血症代理指標，與「植體失敗」不是同一件事；(c) 終點跨處置類型合併，非植牙專屬結論。與植牙專屬回顧（S10）的差異來自處置範圍／介入定義／終點，不是年份演進，不可寫成「新研究推翻舊研究」。

F19｜S9｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 同 F18 微生物學證據顯示單劑預防性用藥可造成短期生態擾動與口腔抗藥性菌叢的選汰。 span：「microbiological evidence indicates that single-dose prophylaxis can promote short-term ecological disturbance and selection of resistant oral flora.」 caveat：來自實驗性研究的推論，非臨床結果指標。

F20｜S10｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 2020-06 發表，檢索至 2018-02，14 篇文獻 預防性抗生素與植體失敗風險降低相關。介入定義（原文）＝「植體手術前給予，以及術前給予並持續至術後即刻（PIFS）」的預防性抗生素；納入的植體中 5,334 支使用術前抗生素、82 支使用 PIFS、3,862 支未使用抗生素。整體風險比 RR 0.47（95% CI 0.39–0.58），NNT 35（95% CI 26.3–48.2）；作者結論寫為「給予預防性抗生素降低了植體失敗風險」，並指出仍需建立標準化用藥療程。 span：「To assess the literature on the efficacy of prophylactic antibiotics prescribed prior to and immediately following implant surgery (PIFS).」／「Fourteen publications were collected」／「5,334 implants were placed with pre-operative antibiotics, 82 implants with antibiotics PIFS and 3,862 placed with no antibiotics」／「The overall risk ratio (RR) was 0.47 (95% CI 0.39-0.58)」／「The number needed to treat (NNT) was 35 (95% CI 26.3-48.2).」／「Administering prophylactic antibiotics reduced the risk of implant failures.」／「Further investigations are recommended to establish a standardised protocol for the proper use of antibiotic regimen.」 caveat：與 F18 結論方向不同，年份、納入條件與終點定義皆不同，需並列呈現而非擇一。介入定義限定：RR 0.47 為含 PIFS 臂在內的 overall RR，原文 AIM 與 CONCLUSION 均未把介入窄化為「僅術前」——不得寫成「術前給予的 RR」；正確寫法為「術前給予以及術前給予並持續至術後即刻（PIFS）」。PIFS 臂僅 82 支植體，佔比小，但既屬合併範圍即須揭露。效應量尺度限定：本條為風險比（RR），與 F18 的均差（MD）不同尺度，不可互換算或直接比大小。metadata 實測（2026-08-06 efetch，HTTP:200）：PublicationType＝`['Journal Article', 'Meta-Analysis', 'Systematic Review']`。

F21｜S1｜confidence: high｜basis: clinical_guideline｜geo: universal｜period: 2015 EAO 第 4 屆共識會議 EAO 第 4 屆共識會議工作組將抗生素預防在植牙手術中的角色、植體周圍炎、病人回報結果（PROMs）與健康經濟列為植牙病人的關鍵議題，並指出抗生素預防屬長期存在對立意見的領域。 span：「This included areas where conflicting opinions exists since long or recently has been expressed, like the role of antibiotic prophylaxis in dental implant surgery and peri-implantitis.」／「Also areas with growing interest and concern such as patient-reported outcome measures (PROMs) and health-economy was included in this review.」 caveat：2015 年共識，後續證據已更新（見 F18、F20）。

F22｜S11｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 檢索 2014-01 至 2024-05，納入 5 篇 對象限無牙上顎（edentulous maxilla）病人、比較即刻／早期／延遲負重的前瞻研究系統性回顧（納入 5 篇，排除顴骨植體）中，臨床端結果指標（ClinROs）無標準化做法，造成報告結果高度異質。 span：「comparing immediate, early, and delayed implant loading protocols in edentulous maxilla patients receiving implant-supported prostheses」／「Zygomatic implants were excluded.」／「Five studies were included, of which four compared immediate versus delayed loading and one study compared immediate versus early loading.」／「ClinROs showed no standardized approach, creating significant heterogeneity in the reported outcomes.」 caveat：僅納入 5 篇研究，對象限無牙上顎，排除顴骨植體。族群限定不得刪：引用本條時必須同時寫出「無牙上顎」，不得寫成「比較不同負重時機的前瞻研究」這種通稱，否則會被讀成整個負重時機領域的通則（與 F23 族群限定同一處理標準）。本條屬研究方法學層級（各研究「用什麼指標測」不統一），不等於臨床上「療程時程沒有標準」；即刻／早期／延遲負重本身在文獻中有既定的分類定義，不得以本條推論成「多久沒有標準答案」。

F23｜S12｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 2021-10 發表，40 篇文章／35 個世代研究 就以植體支持的單顆或短跨距重建、以及覆蓋義齒而言，無強證據支持植體植入或負重的時機會影響病人的不適感、對功能或美觀的滿意度，或整體治療滿意度。 span：「finally 40 articles, representing 35 cohort studies, were included.」／「There is no strong evidence to support that the time for implant placement or loading of implant-supported single or short-span reconstructions or overdentures influence patients´ discomfort, satisfaction with function or esthetics or overall satisfaction with the implant treatment.」 caveat：多數納入研究品質評估有疑慮（some concerns）。族群限定不得刪：本條只涵蓋單顆／短跨距重建與覆蓋義齒，不是對所有植牙治療的全稱否定；全牙弓固定式重建的方向不同，見 F24。本條亦為「病人感受」結論，不得改寫成「療程長度／時程沒有標準」。

F24｜S12｜confidence: low｜basis: peer_reviewed｜geo: universal｜period: 同 F23 無牙病人以植體支持全牙弓固定式重建者，短期內對即刻負重的滿意度較高，但該差異在治療後一年時不明顯。 span：「There is some evidence that studies including edentulous patients rehabilitated with implant-supported full-arch FDPs demonstrate more satisfied patients with immediate than for the early or delayed loaded implant reconstructions after short time, but the difference is not clear one year after treatment.」 caveat：原文自述為「some evidence」，證據強度低。

F25｜S13｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 檢索至 2023-07，納入 12 篇 在重度牙周病（無望或預後可疑牙齒）情境下，植體維護成本加上併發症處置成本，似乎超過治療與維護牙周條件受損牙齒的成本。該回顧納入 12 篇，其中 9 篇談保留牙齒的成本效益、3 篇談以植體取代牙周條件受損牙齒。 span：「Twelve articles were included, of which nine articles discussed the cost-effectiveness of preserving teeth in severe periodontal disease and three articles discussed the effectiveness of implants that replaced the periodontally compromised teeth.」／「implant maintenance cost as well as the cost associated with treating implant complications should be considered. This cost seems to surpass the cost of treatment and maintenance of periodontally compromised teeth.」 caveat：限重度牙周病情境；為相對成本結論，未涉任何金額或幣別，不可外推至其他缺牙情境。研究設計限定：9 篇＋3 篇為兩組互不對照文獻的間接並置，不是同一批病人的頭對頭比較，引用時不得寫成「比較了 A 與 B」。適用性限定：成本效益結論高度依賴各國醫療體系與收費結構，本篇 geo_scope 為 global，不得用來回答任一地的實際費用或划算與否。

F26｜S13｜confidence: medium｜basis: peer_reviewed｜geo: universal｜period: 同 F25 植體為有效的缺牙替代選項，但會出現併發症、需要嚴格維護，並非裝上後即不需再處理。 span：「Implants are an effective choice to replace missing teeth; however, these are not permanent, present complications, and require strict maintenance.」 caveat：為回顧作者之總結陳述。來源情境限定（與 F25 同一篇 S13）：該回顧的對象為重度牙周病（無望或預後可疑牙齒）患者，主題為成本效益；本條是它 CONCLUSIONS 的開場總結，不是一份針對全體植牙病人的預後研究。引用於 TL;DR 或 FAQ 等高抽取率位置時，須同時揭露其來源情境，並以 F1（≥20 年前瞻研究統合分析、GRADE 中等）作為長期結果的主錨；本條只作佐證，不得單獨承載對全體植牙病人的預後宣告。

F27｜S14｜confidence: low｜basis: peer_reviewed｜geo: universal｜period: 2012 發表，質性研究 n=10 質性研究（grounded theory）記錄到：治療前的把關因素包括費用與看牙焦慮；牙醫師的意見與建議是決策過程中決定性的部分，對牙醫師與團隊的信任是接受治療與整體治療經驗的關鍵。 span：「Ten informants participated in the study, all of whom were treated with implant-supported fixed dentures during the past year.」／「gatekeeping factors before treatment, such as cost and dental anxiety, were noted. The dentist's opinion and suggestions were the most decisive part of the decision-making process, and trust in the dentist and dental team was crucial in the decision to undergo treatment」 caveat：10 位受訪者之質性設計，不可推論比例或代表性。

F28｜S15｜confidence: low｜basis: peer_reviewed｜geo: universal｜period: 2024 發表，隨機分組比較 n=32（住院口腔顎面手術病人） 軟質混合飲食（SBD）組較全流質飲食（SFD）組有較高的攝食量數值（63.2% vs. 51.0%）；原文在攝食量這一項未報告 p 值（同段的飲食滿意度 P<0.0001 有報告）。 span：「Thirty-two patients were randomized into two groups: sixteen received SFD and sixteen received SBD.」／「The SBD group had higher dietary intake (63.2% vs. 51.0%) and greater diet satisfaction (80.6 vs. 48.1, P < 0.0001) compared to SFD group.」 caveat：樣本數 32、單一情境（住院口腔顎面手術），非門診植牙病人研究，亦非任何飲品（含咖啡）之專門研究；本文僅作背景使用，不外推為植牙術後飲食指示。統計限定：攝食量差異未報告統計顯著性，只能敘述為數值差異，不得寫成已證實的組間差異。設計描述限定：PubMed PublicationType 僅標示 `Journal Article`（標題自述 comparative study，摘要 METHODS 寫 randomized into two groups），本文因此描述為「隨機分組比較研究」而不寫 RCT。

F29｜S12｜confidence: high｜basis: peer_reviewed｜geo: universal｜period: 同 F23 植牙的療程方案通常包含等待拔牙窩癒合與植體骨整合的期間。 span：「Protocols for implant dentistry, most frequently include periods until healing of the extraction sockets and osseointegration of the implant.」 caveat：為描述性陳述，未給定任何等待天數。

十三、合規註記

  • 本文為衛生教育與醫學新知整理，屬單純衛教與醫學新知之傳遞，未涉招徠就醫；不構成醫療廣告，也不構成診斷或治療建議。
  • 文中所有數據皆為國際文獻中的群體層級研究結果，不能用來推估任何一位病人的個別結果；實際治療方式與效果因人而異，須由牙醫師依個別狀況評估。
  • 本文不為任何治療方式、材料、器材或醫療機構背書，不比較院所，不呈現任何金額或收費資訊。
  • 用藥（含止痛與抗生素）屬處方行為，本文刻意不列藥名與劑量；任何用藥以主治牙醫師處方為準。
  • 出現文中所列之發炎、出血、流膿、傷口裂開、移植材暴露或影像上骨喪失等徵象時，請盡快回診由牙醫師評估。
  • 本文 geo_scope 為 global：不涉任一國之保險給付、收費規定與醫療法規；在地制度請見對應的 TW 正典卡與制度層領域文。
  • 狀態：草稿，未過發布閘門，四語未齊，待 OP 親驗與 owner 終審。

十四、來源清單

全部條目取用日期：2026-08-06。取得方式：NCBI E-utilities（efetch/esearch）與 PubMed 網頁，實測 HTTP 200 並逐字比對 span。

#basis文獻識別碼URL
S1clinical_guidelineThe patient undergoing implant therapy. Summary and consensus statements. The 4th EAO Consensus Conference 2015. *Clin Oral Implants Res*. 2015PMID 26385621／doi:10.1111/clr.12675https://pubmed.ncbi.nlm.nih.gov/26385621/
S2clinical_guidelinePeri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *J Periodontol*. 2018 Jun;89 Suppl 1:S313–S318PMID 29926955／doi:10.1002/JPER.17-0739https://pubmed.ncbi.nlm.nih.gov/29926955/
S3peer_reviewedDental implant survival and marginal bone loss after a minimum of 20 years: systematic review and meta-analysis of prospective studies. *Int J Oral Maxillofac Surg*. 2026PMID 42173763／doi:10.1016/j.ijom.2026.05.011https://pubmed.ncbi.nlm.nih.gov/42173763/
S4peer_reviewedFactors leading to implant failure: An umbrella review of meta-analyses of observational studies and trials. *J Prosthet Dent*. 2026PMID 40425441／doi:10.1016/j.prosdent.2025.04.041https://pubmed.ncbi.nlm.nih.gov/40425441/
S5peer_reviewedOral bone regeneration and associated complications: A systematic review and meta-analysis. *J Stomatol Oral Maxillofac Surg*. 2026PMID 41077306／doi:10.1016/j.jormas.2025.102606https://pubmed.ncbi.nlm.nih.gov/41077306/
S6peer_reviewedBone Regeneration Techniques for Dental Implant Placement Comparing the Effect of Graft Material on Bone Volume and Long-Term Graft Stability: A Systematic Review. *J Oral Implantol*. 2026PMID 42242697／doi:10.1563/aaid-joi-D-24-00238https://pubmed.ncbi.nlm.nih.gov/42242697/
S7peer_reviewedComparative efficacy of immediate implant placement and alveolar ridge preservation after tooth extraction: A comprehensive systematic review and meta-analysis of randomized controlled trials. *Medicine*. 2025 Dec 26PMID 41465916／doi:10.1097/MD.0000000000046832https://pubmed.ncbi.nlm.nih.gov/41465916/
S8peer_reviewedPreemptive Analgesia With Steroidal and Nonsteroidal Anti-Inflammatory Drugs in Dental Implant Surgeries: A Systematic Review. *J Oral Implantol*. 2026 Jun 5PMID 42242696／doi:10.1563/aaid-joi-D-24-00009https://pubmed.ncbi.nlm.nih.gov/42242696/
S9peer_reviewedPerioperative Antimicrobial Prophylaxis for Invasive Dental Procedures: A Systematic Review and Random-Effects Meta-Analysis of Randomized and Placebo-Controlled Studies. *Cureus*. 2026 JanPMID 41640922／doi:10.7759/cureus.100755https://pubmed.ncbi.nlm.nih.gov/41640922/
S10peer_reviewedAntibiotic prophylaxis for implant placement: a systematic review of effects on reduction of implant failure. *Br Dent J*. 2020 JunPMID 32591710／doi:10.1038/s41415-020-1649-9https://pubmed.ncbi.nlm.nih.gov/32591710/
S11peer_reviewedPatient- and Clinician-Reported Outcomes and Outcome Measures Evaluating Timing of Implant Loading in the Edentulous Maxilla: A Systematic Review of Prospective Studies. *Clin Oral Implants Res*. 2026 FebPMID 41732074／doi:10.1111/clr.14451https://pubmed.ncbi.nlm.nih.gov/41732074/
S12peer_reviewedPatient's perception of timing concepts in implant dentistry: A systematic review. *Clin Oral Implants Res*. 2021 OctPMID 34642992／doi:10.1111/clr.13861https://pubmed.ncbi.nlm.nih.gov/34642992/
S13peer_reviewedThe cost-effectiveness of tooth preservation vs implant placement in severe periodontal disease patients: a systematic review. *Quintessence Int*. 2024 Jan 23PMID 37823844／doi:10.3290/j.qi.b4500025https://pubmed.ncbi.nlm.nih.gov/37823844/
S14peer_reviewedGrounded theory on factors involved in the decision-making processes of patients treated with implant therapy. *Int J Prosthodont*. 2012 May-JunPMID 22545258https://pubmed.ncbi.nlm.nih.gov/22545258/
S15peer_reviewedImpact of postoperative dietary types on nutrition and treatment prognosis in hospitalized patients undergoing oral and maxillofacial surgery: a comparative study. *Korean J Community Nutr*. 2024 AprPMID 41472659／doi:10.5720/kjcn.2024.29.2.129https://pubmed.ncbi.nlm.nih.gov/41472659/
S16peer_reviewedPost-extraction dimensional changes: A systematic review and meta-analysis. *J Clin Periodontol*. 2021 Jan;48(1):126–144PMID 33067890／doi:10.1111/jcpe.13390https://pubmed.ncbi.nlm.nih.gov/33067890/

basis 統計：clinical_guideline 2／peer_reviewed 14／合計 16（peer_reviewed ≥6 達標；全篇 sources ≥8 達標）。

未採用之錨定條目說明：P01 錨定檔另收有台灣法規兩條（醫療法第 63 條、全民健康保險法第 51 條）。依本篇 global 定調，在地法規與給付制度不得作為本文之 basis，故兩條均未進入 F-Units 與本來源清單；相關內容一律以下鏈指向 TW 正典卡與制度層領域文處理。

FAQ

Q1. 植牙可以用多久？
在追蹤 20 年以上的前瞻研究統合分析中，20 年植體存活率為 93.0%（95% CI 91.6–94.1%），合併平均邊緣骨喪失 1.11 mm，證據確定性評為中等且異質性高 [F1]。這是群體統計，不能推估個人結果。另一篇以重度牙周病患者為對象的成本效益回顧則總結：植體並非永久、會出現併發症、需要嚴格維護 [F26]。
Q1. インプラントはどれくらいもちますか？ — 20 年以上追跡した前向き研究のメタアナリシスでは、20 年のインプラント生存率は 93.0%（95% CI 91.6–94.1%）、統合された平均辺縁骨吸収は 1.11 mm であり、エビデンスの確実性は中等度、異質性は高いと評価されています [F1]。これは集団の統計であって、個人の結果を推定することはできません。また、重度歯周病の患者を対象とした費用対効果のレビューは、インプラントは永久的ではなく、合併症が生じ、厳格なメインテナンスを必要とすると総括しています [F26]。
Q1. How long does an implant last? — In the meta-analysis of prospective studies with more than 20 years of follow-up, the 20-year implant survival rate was 93.0% (95% CI 91.6–94.1%) and the pooled mean marginal bone loss was 1.11 mm, with the certainty of evidence rated moderate and heterogeneity high [F1]. These are population statistics and cannot be used to estimate an individual outcome. A separate cost-effectiveness review, whose subjects were patients with severe periodontal disease, summarises instead that implants are not permanent, present complications and require strict maintenance [F26].
Q2. 骨頭不夠就不能植牙嗎？
缺牙後的生理性骨吸收常使可用骨量不足，因此才發展出引導骨再生、上顎竇增高與齒槽脊保存等骨增生術式 [F14]；移植材料分四類，文獻對何者較優尚無共識 [F13]。骨增生本身帶有併發症：一篇聚焦上顎骨增生的回顧量化了上顎竇增高、引導骨再生、onlay 骨移植與混合術式的併發症合併發生率（該回顧未涵蓋齒槽脊保存，數字亦不外推至下顎）[F15]。是否適用須由牙醫師評估。
Q2. 骨が足りなければインプラントはできないのですか？ — 歯を失った後の生理的な骨吸収により利用できる骨量が不足することが多く、そのため骨誘導再生、上顎洞挙上、歯槽堤保存などの骨造成術式が発展してきました [F14]。移植材料は四種類に分かれ、どれが優れているかについて文献に合意はありません [F13]。骨造成そのものにも合併症があります。上顎の骨造成に焦点を当てたレビューが、上顎洞挙上、骨誘導再生、onlay 骨移植、混合術式の合併症の統合発生率を定量化しています（当該レビューは歯槽堤保存を含まず、数値を下顎に外挿することもできません）[F15]。適用できるかどうかは歯科医師の評価が必要です。
Q2. Does insufficient bone mean an implant is impossible? — The physiological bone resorption that follows tooth loss often leaves the available bone volume insufficient, which is why bone augmentation techniques such as guided bone regeneration, sinus augmentation and alveolar ridge preservation were developed [F14]; graft materials fall into four types and the literature has no consensus on which is superior [F13]. Bone augmentation itself carries complications: a review focused on the maxilla quantified the pooled complication rates of sinus lift, guided bone regeneration, onlay grafting and mixed techniques (that review does not cover alveolar ridge preservation, and its figures are not extrapolated to the mandible) [F15]. Whether it applies in a given case must be assessed by a dentist.
Q3. 植牙一定要吃抗生素嗎？
這是國際文獻中長期存在爭議的題目 [F21]。兩份回顧問的其實不是同一件事：2020 年那篇限於植體植入手術、終點為植體失敗，其介入為術前給予以及術前給予並持續至術後即刻（PIFS）的預防性抗生素，整體風險比 RR 0.47（NNT 35）[F20]；2026 年那篇涵蓋各類侵入性牙科處置，介入定義為全身性抗生素與／或局部抗菌劑（含 chlorhexidine 漱口水），合併終點為早期感染與／或菌血症相關的代理指標，未顯示統計上顯著的整體降低 [F18]。兩者的效應量尺度也不同（前者為風險比 RR、後者為均差 MD），不能直接比大小；PubMed 對後者登錄的文獻型別亦僅為 `Journal Article, Review` [F18][F20]。後者也提醒單劑預防用藥可能擾動口腔菌相與選汰抗藥性菌株 [F19]。用藥以主治牙醫師處方為準。
Q3. インプラントでは必ず抗菌薬を飲まなければいけませんか？ — これは国際的な文献の中で長く議論が続いているテーマです [F21]。二つのレビューが問うているのは、実は同じことではありません。2020 年の論文はインプラント埋入手術に限られ、エンドポイントはインプラントの失敗で、その介入は術前投与および術前投与に加えて術直後まで継続する投与（PIFS）の予防的抗菌薬であり、全体のリスク比は RR 0.47（NNT 35）です [F20]。2026 年の論文は各種の侵襲的な歯科処置を対象とし、介入の定義は全身性の抗菌薬および／または局所の抗菌薬（chlorhexidine の洗口液を含む）で、統合エンドポイントは早期感染および／または菌血症関連の代替指標であり、統計学的に有意な全体的低下は示されていません [F18]。両者の効果量の尺度も異なり（前者はリスク比 RR、後者は平均差 MD）、そのまま大小を比べることはできません。PubMed が後者に登録した文献タイプも `Journal Article, Review` のみです [F18][F20]。後者は、単回投与の予防投与が口腔細菌叢を攪乱し耐性菌を選択しうることも注意喚起しています [F19]。薬の使用は主治の歯科医師の処方によります。
Q3. Do antibiotics always have to be taken for an implant? — This is a long-standing point of controversy in the international literature [F21]. The two reviews are not in fact asking the same question: the 2020 one is limited to implant placement surgery with implant failure as its endpoint, its intervention being prophylactic antibiotics given pre-operatively and given pre-operatively with continuation immediately post-operatively (PIFS), with an overall risk ratio of RR 0.47 (NNT 35) [F20]; the 2026 one covers invasive dental procedures of all kinds, defines its intervention as systemic antibiotics and/or local antiseptics (including chlorhexidine mouthwash), and pools a surrogate endpoint of early infection and/or bacteremia, showing no statistically significant overall reduction [F18]. The two also use different effect-size scales (a risk ratio RR for the former, a mean difference MD for the latter) and cannot be compared directly for magnitude; PubMed also registers the latter's publication type merely as `Journal Article, Review` [F18][F20]. The latter further cautions that single-dose prophylaxis may disturb the oral flora and select for resistant strains [F19]. Medication follows the prescription of the treating dentist.

來源錨定

引用本文

km 編輯部・《植牙全指南（領域總覽）：從評估、骨處理、手術到長期維護｜證據鏈》・IDAEO 知識庫・2026-08-13・https://km.idaeo.ai/reports/dental-pillar-implant-evidence

相關文章

更新 2026-08-13T14:17:35.275Z · server-rendered · four-language · IDAEO 知識庫